Tag
Lupin Limited
10 articles
Lupin delivered a strong fiscal year 2026, with net profit rising 62% to ₹53.56 billion and revenue increasing 24% to ₹274.88 billion, driven by robust performance in both the U.S. and India. The company reported a significant expansion in EBITDA margins, reaching 33.6% for the full year. Key developments included the U.S. launch of Dapagliflozin, the acquisition of VISUfarma, and European biosimilar approval for Ranibizumab, alongside receiving US FDA approval for Glycerol Phenylbutyrate. Lupin anticipates high-single digit revenue growth and EBITDA margins around 25% in fiscal 2027, while maintaining a strong net cash position of ₹4,636 crores and actively pursuing strategic acquisitions.
Lupin Debuts in Dow Jones Best-in-Class Indices
Lupin Limited announced its first-time inclusion in both Dow Jones Best-in-Class World Index and Emerging Markets Index for 2026.
The recognition follows Lupin's top 1% global ranking in S&P Global CS
Lupin Receives Tentative FDA Approval for Revefenacin
Lupin received tentative FDA approval for generic Revefenacin Inhalation Solution, 175 mcg/3 mL unit-dose vials.
The product is bioequivalent to Mylan's Yupelri® for COPD maintenance treatment with $2
Lupin Inaugurates Delhi Neuro-Rehabilitation Center Atharv Ability
Lupin Limited inaugurates Atharv Ability, a multidisciplinary neuro-rehabilitation center in Delhi, expanding its healthcare services portfolio.
The center offers advanced technology-enabled care for
Lupin Q4 FY26 Net Profit Up 68% YoY
Lupin reported a 68% YoY EBITDA growth to INR 2,171 crores in Q4 FY26, marking its 15th consecutive quarter of growth.
US sales reached a record USD 1.318 billion for FY26, driven by new complex produ
Lupin Q4 FY26 Earnings Call Audio Available
Lupin Limited intimates exchanges of audio recording availability for its Q4 FY26 earnings call held on May 8, 2026.
The earnings call was conducted digitally at 16:00 hrs IST as part of regulatory co
Lupin Q4 FY26 Net Profit Jumps 89% YoY
Lupin reported Q4 FY26 net sales of ₹73,919 crore, up 32.9% YoY, with net income surging 89% to ₹14,604 crore.
EBITDA margin expanded to 29.4% driven by strong US sales growth and operational efficien
Lupin FY2026 Net Profit Rises 62% to ₹53,555 Mn
Lupin reported FY2026 consolidated PAT of ₹53,555 Mn, a 62.0% YoY increase, with sales growing 23.9% to ₹274,875 Mn.
EBITDA margin expanded significantly by 890 bps to 33.6% for the full year, driven
Lupin Appoints Deloitte as New Statutory Auditors
Lupin's Board recommends appointing Deloitte Haskins & Sells as Statutory Auditors for a five-year term, subject to shareholder approval at the 44th AGM.
Outgoing auditor B S R & Co. LLP is completing
Lupin FY26 Net Profit Rises 60% to ₹63.7B
Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, and recommended a dividend of ₹18 per share.
Standalone net profit for FY26 increased to ₹63,66
Lupin Receives US FDA Approval for Glycerol Phenylbutyrate
Lupin Limited receives US FDA approval for its Abbreviated New Drug Application for Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL.
The approved product is bioequivalent to Ravicti® Oral Liquid